ContraFect Corporation Showcases CF-301 at ICAAC 2013 Meeting in Denver, CO
YONKERS, NY -- (Marketwired) -- 08/22/13 -- ContraFect Corporation, developing biotherapeutics for life-threatening infectious diseases, is pleased to announce that ContraFect has been selected to present four posters at the 53rd ICAAC conference (the meeting of the American Society for Microbiology -- "the world's premier international conference on antimicrobial agents and infectious diseases" -- http://www.icaac.org/). This year's ICAAC conference will take place September 10-13, 2013 at the Denver Convention Center in Denver, CO.
ContraFect's scientists will introduce their lead drug candidate, CF-301, an anti-infective agent with a novel mechanism of action that demonstrates potent activity against all drug-resistant and drug-sensitive forms of Staphylococcus aureus ("Staph"). CF-301's unique and differentiating properties will be displayed in posters discussing its potency (F-648), rapid bactericidal and synergistic activity (F-649), superiority as a combination therapy with anti-Staph antibiotics for the treatment of Staph bacteremia in animal models of the disease (F-647) and activity against biofilms (F-646).
"We are delighted to present our novel drug, CF-301, to the infectious disease community," stated Robert Nowinski, ContraFect's founder and chief executive officer. "Our data reflects ContraFect's new alternative approach to treating the life-threatening infectious disease of Staph bacteremia."
ContraFect posters and scientists will be available on September 11 from 11:00am to 1:00 pm (MT). Poster F-647 will be highlighted in the ASM Press Room.
CF-301, is a bacteriophage lysin, which is an enzyme that digests bacterial cell walls, killing bacteria immediately upon contact. CF-301 has specificity for Staphylococcus aureus (Staph), and Group A and Group B streptococci, and has displayed activity against all forms of Staph, including methicillin-resistant (MRSA) and vancomycin-resistant isolates (VISA/VRSA). The initial indication being pursued for CF-301 is Staph bacteremia, a blood borne infection that causes 30,000 deaths per year in the U.S. alone.
ContraFect Corporation is a biotechnology company pioneering the use of Lysins and Monoclonal Antibodies to treat life-threatening infectious diseases. ContraFect's initial products include new agents to treat diseases such as MRSA (drug-resistant staphylococcus bacteria) and influenza. Its scientific strategy focuses on the use of combination therapies, where it believes that the company's products will overcome high rates of mutation and resistance observed in microbes.
About the ICAAC
ICAAC, the premier conference on antimicrobial agents and infectious diseases, showcases the latest-breaking science and lectures from top researchers from around the world. With over 60% of its attendees living outside of the United States, ICAAC provides a rare opportunity to bring together the field's foremost leaders to discuss the state of infection control and prevention on a global scale. Through oral and poster presentations, 10,000 physicians, clinical microbiologists, researchers, and pharmacists will come together to share their research, discover the latest breakthroughs, and work towards fostering global solutions to the problems of infectious diseases and antimicrobial agents.
Safe Harbor Statement
This release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward looking statements. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.
Source: ContraFect Corporation
Released August 22, 2013